My opinion on the high share price of 62c is that the market was forecasting a Hervaxx deal. The market is always forward looking, putting the cart before the horse. So since Hervaxx didn't commercialise and is now not being talked about by Imugene the value has been removed. Obviously since then CF33 has advanced but the market is not assuming much value to this yet.
